AR035800A1 - Pirimidin-2,4,6-trionas 5,5-disustituidas, composiciones farmaceuticas que las comprenden, y el uso de dichos compuestos en la preparacion de medicamentos - Google Patents
Pirimidin-2,4,6-trionas 5,5-disustituidas, composiciones farmaceuticas que las comprenden, y el uso de dichos compuestos en la preparacion de medicamentosInfo
- Publication number
- AR035800A1 AR035800A1 ARP020101143A ARP020101143A AR035800A1 AR 035800 A1 AR035800 A1 AR 035800A1 AR P020101143 A ARP020101143 A AR P020101143A AR P020101143 A ARP020101143 A AR P020101143A AR 035800 A1 AR035800 A1 AR 035800A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- substituted
- groups
- atoms
- trionas
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 phenoxy, phenylthio, phenylsulfinyl Chemical group 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Pirimidin-2,4,6-trionas 5,5-disustituidas de fórmula (1) en donde R1 representa un radical de fenilo, fenoxilo, feniltio, fenilsulfinilo, fenilsulfonilo, fenilamino o fenilmetilo, en donde la fracción de fenilo puede estar sustituida por uno o más átomos de halógeno, alcoxi, alquilo de C1-6, ciano, o grupos nitro, prefiriéndose sustituciones en posición para y/o meta por uno a dos sustituyentes; R2 representa hidrógeno; R3 representa hidrógeno, alquilo inferior, opcionalmente interrumpido por uno o más átomos de O, N o S y opcionalmente e independientemente entre sí sustituidos por uno o más grupos hidroxilo y grupos oxo; R4 representa alquilo inferior, opcionalmente interrumpido por uno o más átomos de O, N o S e independientemente uno de otro sustituido por uno o más grupos de hidroxilo y oxo, arilo, aralquilo, hetarilo o un grupo acilo; R2 y R3 o R3 y R4 junto con el átomo de nitrógeno al que están enlazados pueden formar también un anillo de piperacina que en el último caso puede ser sustituido en el segundo átomo de nitrógeno por arilo, aralquilo o un grupo hetarilo; así como también sus profármacos y sales farmacéuticamente aceptables. Dichos compuestos exhiben actividad inhibidora de metaloproteinasa, y son útiles en el tratamiento de tumores y metástasis. También se dan a conocer composiciones farmacéuticas que comprenden dichos compuestos y el uso de tales compuestos en la preparación de medicamentos
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01107714 | 2001-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035800A1 true AR035800A1 (es) | 2004-07-14 |
Family
ID=8176973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101143A AR035800A1 (es) | 2001-03-30 | 2002-03-27 | Pirimidin-2,4,6-trionas 5,5-disustituidas, composiciones farmaceuticas que las comprenden, y el uso de dichos compuestos en la preparacion de medicamentos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6716845B2 (es) |
| EP (1) | EP1383746A2 (es) |
| JP (1) | JP2004533425A (es) |
| KR (1) | KR20030086335A (es) |
| CN (1) | CN1273454C (es) |
| AR (1) | AR035800A1 (es) |
| AU (1) | AU2002302470C1 (es) |
| BR (1) | BR0208440A (es) |
| CA (1) | CA2442354A1 (es) |
| MX (1) | MXPA03008588A (es) |
| PA (1) | PA8542001A1 (es) |
| PE (1) | PE20021101A1 (es) |
| UY (1) | UY27239A1 (es) |
| WO (1) | WO2002079170A2 (es) |
| ZA (1) | ZA200306615B (es) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
| GB8726714D0 (en) | 1987-11-14 | 1987-12-16 | Beecham Group Plc | Compounds |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5239078A (en) | 1990-11-21 | 1993-08-24 | Glycomed Incorporated | Matrix metalloprotease inhibitors |
| JPH05503720A (ja) | 1990-12-03 | 1993-06-17 | セルテック リミテッド | ペプチジル誘導体 |
| CA2058797A1 (en) | 1991-02-01 | 1992-08-02 | Michael John Broadhurst | Amino acid derivatives |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| PT874830E (pt) | 1995-12-08 | 2003-06-30 | Agouron Pharma | Inibidor de metaloproteinases composicao farmaceutica contendo este inibidor e a utilizacao farmaceutica e metodo util para a sua preparacao |
| DE19548624A1 (de) * | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19726427A1 (de) * | 1997-06-23 | 1998-12-24 | Boehringer Mannheim Gmbh | Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| AR033651A1 (es) | 1999-10-01 | 2004-01-07 | Hoffmann La Roche | Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento |
-
2002
- 2002-02-25 US US10/082,907 patent/US6716845B2/en not_active Expired - Fee Related
- 2002-03-26 BR BR0208440-6A patent/BR0208440A/pt not_active IP Right Cessation
- 2002-03-26 PE PE2002000242A patent/PE20021101A1/es not_active Application Discontinuation
- 2002-03-26 MX MXPA03008588A patent/MXPA03008588A/es active IP Right Grant
- 2002-03-26 CN CNB028074912A patent/CN1273454C/zh not_active Expired - Fee Related
- 2002-03-26 CA CA002442354A patent/CA2442354A1/en not_active Abandoned
- 2002-03-26 KR KR10-2003-7012814A patent/KR20030086335A/ko not_active Ceased
- 2002-03-26 JP JP2002577797A patent/JP2004533425A/ja active Pending
- 2002-03-26 AU AU2002302470A patent/AU2002302470C1/en not_active Ceased
- 2002-03-26 WO PCT/EP2002/003366 patent/WO2002079170A2/en not_active Ceased
- 2002-03-26 EP EP02730063A patent/EP1383746A2/en not_active Withdrawn
- 2002-03-27 AR ARP020101143A patent/AR035800A1/es unknown
- 2002-03-27 UY UY27239A patent/UY27239A1/es not_active Application Discontinuation
- 2002-03-27 PA PA20028542001A patent/PA8542001A1/es unknown
-
2003
- 2003-08-25 ZA ZA200306615A patent/ZA200306615B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1383746A2 (en) | 2004-01-28 |
| US20020187991A1 (en) | 2002-12-12 |
| WO2002079170A3 (en) | 2003-11-27 |
| UY27239A1 (es) | 2002-09-30 |
| AU2002302470B2 (en) | 2008-02-14 |
| BR0208440A (pt) | 2004-03-30 |
| KR20030086335A (ko) | 2003-11-07 |
| CA2442354A1 (en) | 2002-10-10 |
| ZA200306615B (en) | 2004-11-25 |
| WO2002079170A2 (en) | 2002-10-10 |
| US6716845B2 (en) | 2004-04-06 |
| PA8542001A1 (es) | 2002-10-28 |
| JP2004533425A (ja) | 2004-11-04 |
| AU2002302470C1 (en) | 2008-07-24 |
| CN1553901A (zh) | 2004-12-08 |
| CN1273454C (zh) | 2006-09-06 |
| MXPA03008588A (es) | 2003-12-08 |
| PE20021101A1 (es) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9904652D0 (sv) | Novel Compounds | |
| BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR034390A1 (es) | Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa | |
| AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
| BRPI0616799B8 (pt) | derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| CY1108529T1 (el) | Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| AR015449A1 (es) | Derivados piperidil- o peperazinil-dihidro sustituidos-2h-1-benzopirano composicion farmaceutica que los contiene, su uso para la elaboracion de unmedicamento, procedimiento para su preparacion y compuesto intermediario para su exclusivo uso en dicho procedimiento | |
| AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
| BR9916669A (pt) | Uso de derivados de ácidos 4-biarilbutìricos e 5-biarilpentanóicos substituìdos como inibidores de metaloproteases de matriz para o tratamento de doenças respiratórias | |
| CO5540385A2 (es) | Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen | |
| CO5580721A2 (es) | Composicion fungicida basada en al menos un derivado de piridilmetilbenzamida y al menos un derivado de ditiocarbamato | |
| BRPI0407386A (pt) | Derivados de álcool de amino, composições farmacêuticas contendo os mesmos e uso destes | |
| AR072486A1 (es) | Derivados de benzotiadiazinas cicloalquiladas su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR029468A1 (es) | Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR035800A1 (es) | Pirimidin-2,4,6-trionas 5,5-disustituidas, composiciones farmaceuticas que las comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| ES2172294T3 (es) | Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR033651A1 (es) | Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |